UCLA is a national and international leader in the breadth and excellent quality of teaching, research, health, education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.. in both cases, they were offered the same amount of money, but in one case, it is fair and in the other case it is not, said Tabibnia. – Nearly half of the ,, people has only 20 to 30 % of the total money to accept, but when they accepted these unfair offers, most the brain reward circuitry was not activated; those regions of the brain were for the activation for the activation fair Less.
In the study the subjects were asked whether they accept or decline another person’s offer, to divide money in a particular way. When they went, so that neither she nor the person, the offer anything anything. Some of the offers were fair, such as receiving $ 5 from $ 10 or $ 12, while others unfairly, such as receiving $ 5 from $ 23.
The activated brain regions are the ventral striatum and ventromedial prefrontal cortex. People share the ventral striatum of rats, mice and monkeys, said Tabibnia. – Fairness is activating the same part of the brain in one casehe food response in rats, she said This is consistent with the notion that being treated fairly satisfies a basic need, she added.High-dose busulfan at Lausanne University Hospital at Stem Cell Reports.
We News reporters reported in that additional information, contact T. CHU Vaudois, Lausanne Univ Hosp, COMPREHENSIVE Canc centers, Switzerland-1011 Lausanne, Switzerland .
Now let update the first. Results .. Contain keywords for this news articles: Brain, of Lausanne, lymphoma, oncology, hematology, Switzerland, Quality of Life, Diseases Lymphatic Diseases, Stem Cell Research, Central Nervous System, immunoproliferative disorders, lymphoproliferative disorders.
Using a News Reporter Staff News Editor on Recent Hematology Week studies results of about stem cells According, according to coverage from Lausanne, Switzerland, with NewsRx reporters. Oxford University Press, We have already reported the findings of a phase II trial of patients using newly diagnosed primary CNS lymphoma with a autologous peripheral blood stem cell and handled response customized whole-brain radiotherapy .